Glucagon-like peptide-1 receptor (GLP-1R) agonists, a class of novel hypoglycemic drugs, have exhibited therapeutic effects on multiple metabolic syndromes through diverse mechanisms, including antioxidant, anti-inflammatory, and immunomodulatory actions [4,5,6,7]. Here, GLP1R is linked to metabolic syndrome.